Previous 10 | Next 10 |
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-04-05 13:51:53 ET Summary As the retirement crisis looms, urgent action is key. The financial industry's failure to address rising retirement costs exacerbates the situation. Investing in dividend-growth stocks emerges as a crucial strategy. Realty Income, NextEra Energy, Pep...
2024-04-03 12:30:02 ET UBS analyst issues BUY recommendation for AMGN on April 3, 2024 11:00AM ET. The previous analyst recommendation was Buy. AMGN was trading at $275.52 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
2024-04-03 11:28:49 ET Summary "The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.”–Dow Jones & Co. The highest-...
2024-04-02 03:42:59 ET Summary Successful retirement planning starts many years prior, especially amidst high inflation and skyrocketing home prices. Reaching retirement with enough money saved up, to live comfortably is only a part of the equation. Each individual has differe...
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
2024-03-31 11:15:13 ET Summary Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candidate MariTide and other promising treatments in it...
2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...